Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
Earnings Data
Report Date
Mar 09, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.29Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial stability, with strong support from payers and successful trial execution. However, challenges such as market pricing pressure and potential enrollment difficulties in diabetic retinopathy trials were noted.Company Guidance
SOL-R Reaches Target Randomization
SOL-R has reached its target randomization of 555 subjects, marking a significant milestone and reflecting exceptional execution and investigator enthusiasm.
Financial Strength
Ocular ended Q3 2025 with approximately $345 million in cash, not including $445 million in net proceeds from an October equity financing, providing a cash runway into 2028.
Potential Superiority Label
AXPAXLI is expected to be the first and only therapy with a superiority label in wet AMD compared to a single dose of anti-VEGF, which could change market dynamics.
HELIOS Program Launch
The HELIOS program for diabetic retinopathy aims to capture the entire spectrum of diabetic retinal disease through superiority trials HELIOS-2 and HELIOS-3.
Positive Feedback From Payers
Payers have expressed enthusiasm about AXPAXLI's potential durability and clinical differentiation, indicating strong market support.
OCUL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OCUL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $11.41 | $10.90 | -4.47% |
Aug 05, 2025 | $12.35 | $12.00 | -2.83% |
May 05, 2025 | $8.80 | $7.73 | -12.16% |
Mar 03, 2025 | $7.14 | $5.92 | -17.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ocular Therapeutix (OCUL) report earnings?
Ocular Therapeutix (OCUL) is schdueled to report earning on Mar 09, 2026, After Close (Confirmed).
What is Ocular Therapeutix (OCUL) earnings time?
Ocular Therapeutix (OCUL) earnings time is at Mar 09, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OCUL EPS forecast?
OCUL EPS forecast for the fiscal quarter 2025 (Q4) is -0.32.